Research and development

Our R&D is focussed on the development of new nanomedicines on three therapeutic areas with clearly unmet medical needs: oncology, inflammatory diseases, and rare diseases. We aim to advance to clinical phases with key collaborators and partners.

We are focussing on products that exploit the advantages of our technology for delivering potent and efficient gene therapies and gene editing molecules, and therapeutic peptides.

All the knowledge gathered by developing our R&D portfolio translates into critical know-how and information that feeds DIVERSA’s reagents portfolio and increases the value of our co-development services.